Starling Oncology, Inc. filed a Form 8-K with the SEC on September 2, 2026, disclosing that board member Brad Hively notified the company on September 1, 2026, of his decision not to stand for re-election at the 2027 annual meeting of stockholders.
Key Highlights
- Director departure notice: Brad Hively informed Starling Oncology on September 1, 2026, that he will not stand for re-election to the Board at the 2027 annual meeting of stockholders.
- Continued board service: Mr. Hively is expected to remain a director until the 2027 annual meeting.
- Immediate role changes: Effective immediately, Mr. Hively no longer serves as Vice Chairman of the Board or as a member of the Compliance Committee or any other board committees.
- No disagreement cited: According to the filing, Mr. Hively's decision "is not the result of any disagreement between the Company and him on any matter relating to Company's operations, policies or practices."
- Signed by: The report was signed by Minh Merchant, Chief Legal Officer of Starling Oncology, Inc.
Brad Hively Steps Down from Leadership Roles at Starling Oncology Board
Starling Oncology, Inc. (NASDAQ:STLN), a Delaware-incorporated company headquartered at 18000 Studebaker Road, Suite 800, Cerritos, CA 90703, disclosed through a current report that Brad Hively notified the company of his intention not to seek re-election when his board term comes up at the 2027 annual meeting of stockholders. The event date of the filing is September 1, 2026.
According to the filing, Mr. Hively's departure from leadership roles on the Board was effective immediately upon his notification. Specifically, he will no longer serve as Vice Chairman of the Board or as a member of the Compliance Committee or any other committees of the Board, though he is expected to continue as a director of the company until the 2027 annual meeting. The filing was made under Item 5.02, which covers departures and appointments of directors and certain officers.
The company stated explicitly that Mr. Hively's decision not to stand for re-election "is not the result of any disagreement between the Company and him on any matter relating to Company's operations, policies or practices." Chief Legal Officer Minh Merchant signed the report on behalf of Starling Oncology, Inc.
What Was Disclosed
Starling Oncology disclosed that director Brad Hively will not seek re-election at the 2027 annual meeting, that he immediately vacated his roles as Vice Chairman and committee member, and that no disagreement with the company prompted his decision.




Please wait processing your request...